https://covid19.nih.gov/nih-strategic-response-covid-19
Followed link on fda trials page to the above.
Seems to me taking their Mission Statement seriously and having hands on management to find answers.
Running another trial with Remestemcel-L in a timely manner might not be out of the question?
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-178
-
- There are more pages in this discussion • 246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.263M | 4.474M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 202313 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 57724 | 12 |
View Market Depth
| Last trade - 15.30pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |